Niagen Bioscience Inc [NAGE] stock is trading at $6.71, up 2.91%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling.
From an analyst’s perspective:
Niagen Bioscience Inc [NASDAQ: NAGE] stock has seen the most recent analyst activity on May 27, 2025, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $13. Previously, Oppenheimer downgraded its rating to Perform on August 16, 2022. On August 11, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $2.40 on the stock. ROTH Capital started tracking the stock assigning a Buy rating and suggested a price target of $7 on March 08, 2022. Oppenheimer initiated its recommendation with a Outperform and recommended $6 as its price target on October 16, 2019. B. Riley FBR started tracking with a Buy rating for this stock on February 14, 2019, and assigned it a price target of $7.
Niagen Bioscience Inc [NAGE] stock has fluctuated between $5.16 and $14.69 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Niagen Bioscience Inc [NASDAQ: NAGE] shares were valued at $6.71 at the most recent close of the market. An investor can expect a potential return of 108.64% based on the average NAGE price forecast.
Analyzing the NAGE fundamentals
Niagen Bioscience Inc [NASDAQ:NAGE] reported sales of 124.71M for the trailing twelve months, which represents a growth of 32.86%. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.19, Equity is 0.35 and Total Capital is 0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.47 points at the first support level, and at 6.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.00, and for the 2nd resistance point, it is at 7.30.
Ratios To Look Out For
For context, Niagen Bioscience Inc’s Current Ratio is 4.12. In addition, the Quick Ratio stands at 3.29 and the Cash Ratio stands at 2.7. Considering the valuation of this stock, the price to sales ratio is 4.29, the price to book ratio is 7.56 and price to earnings (TTM) ratio is 27.57.
Transactions by insiders
Recent insider trading involved Pamir Ozan, Chief Financial Officer, that happened on Nov 14 ’25 when 4465.0 shares were purchased. Chief Financial Officer, Pamir Ozan completed a deal on Nov 14 ’25 to buy 2220.0 shares. Meanwhile, SVP, General Counsel Lopez Carlos Luis bought 273.0 shares on Mar 07 ’25.
